Selpercatinib
- Generic Name
- Selpercatinib
- Brand Names
- Retevmo, Retsevmo
- Drug Type
- Small Molecule
- Chemical Formula
- C29H31N7O3
- CAS Number
- 2152628-33-4
- Unique Ingredient Identifier
- CEGM9YBNGD
- Background
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes. Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including cabozantinib, ponatinib, sorafenib, sunitinib, and vandetanib, have shown efficacy in RET-dri...
- Indication
Selpercatinib is approved to treat:
Selpercatinib is currently approved for these indications under an accelerated approval scheme and continued approval may be contingent on future confirmatory trials.
- Associated Conditions
- Locally Advanced Solid Neoplasm, Metastatic Solid Neoplasm, Advanced RET-fusion thyroid cancer, Advanced RET-mutant medullary thyroid cancer, Metastatic RET-fusion Non Small Cell Lung Cancer, Metastatic RET-fusion thyroid cancer, Metastatic RET-mutant medullary thyroid cancer
- Associated Therapies
- -
A Study of Effects of Selpercatinib (LY3527723) on Midazolam in Healthy Participants
- First Posted Date
- 2022-04-21
- Last Posted Date
- 2022-04-21
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 16
- Registration Number
- NCT05338476
- Locations
- 🇺🇸
Celerion, Tempe, Arizona, United States
A Study of Selpercatinib (LY3527723) in Healthy Participants
- First Posted Date
- 2022-04-21
- Last Posted Date
- 2022-04-21
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 18
- Registration Number
- NCT05338515
- Locations
- 🇺🇸
Celerion, Tempe, Arizona, United States
A Study of Effects of Itraconazole and Rifampin on Selpercatinib (LY3527723) in Healthy Participants
- First Posted Date
- 2022-04-21
- Last Posted Date
- 2022-04-21
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 24
- Registration Number
- NCT05338489
- Locations
- 🇺🇸
Celerion, Tempe, Arizona, United States
Study of H2 Antagonist and a Proton Pump Inhibitor of Selpercatinib in Healthy Participants
- First Posted Date
- 2022-04-21
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 20
- Registration Number
- NCT05338502
- Locations
- 🇺🇸
Covance Clinical Research Unit, Inc., Madison, Wisconsin, United States
A Study of the Effect of Food on Selpercatinib (LY3527723) in Healthy Participants
- First Posted Date
- 2022-04-12
- Last Posted Date
- 2022-07-13
- Lead Sponsor
- Loxo Oncology, Inc.
- Target Recruit Count
- 46
- Registration Number
- NCT05324124
- Locations
- 🇸🇬
Lilly Centre for Clinical Pharmacology, Singapore, Singapore
A Relative Bioavailability Study of Selpercatinib (LY3527723) in Healthy Participants
- First Posted Date
- 2021-11-29
- Last Posted Date
- 2022-04-15
- Lead Sponsor
- Loxo Oncology, Inc.
- Target Recruit Count
- 42
- Registration Number
- NCT05136404
- Locations
- 🇺🇸
LabCorp CRU, Inc., Daytona Beach, Florida, United States
A Study Comparing Two Formulations of Selpercatinib (LY3527723) in Healthy Participants
- First Posted Date
- 2021-10-22
- Last Posted Date
- 2022-08-18
- Lead Sponsor
- Loxo Oncology, Inc.
- Target Recruit Count
- 224
- Registration Number
- NCT05089019
- Locations
- 🇺🇸
LabCorp CRU, Inc., Madison, Wisconsin, United States
🇺🇸Covance Dallas, Dallas, Texas, United States
🇺🇸Anaheim Clinical Trials, LLC, Anaheim, California, United States
A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)
- Conditions
- Interventions
- First Posted Date
- 2021-03-26
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Loxo Oncology, Inc.
- Target Recruit Count
- 170
- Registration Number
- NCT04819100
- Locations
- 🇺🇸
UCLA Hematology/Oncology - Santa Monica, Los Angeles, California, United States
🇺🇸Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, California, United States
🇺🇸GenesisCare, Aventura, Florida, United States
A Drug Drug Interaction (DDI) Study of Selpercatinib and Dabigatran in Healthy Participants
- First Posted Date
- 2021-03-04
- Last Posted Date
- 2024-05-24
- Lead Sponsor
- Loxo Oncology, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT04782076
- Locations
- 🇺🇸
Covance Clinical Research Inc, Daytona Beach, Florida, United States
Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-02-18
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT04759911
- Locations
- 🇺🇸
University of Michigan Health Systems, Ann Arbor, Michigan, United States
🇺🇸M D Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.